News | October 15, 2021
Expect normal quarter in Q2FY22: Emkay
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
The consortium envisages carrying out surveillance of important bacterial, viral and parasitic infections of zoonotic as well as transboundary pathogens
_256_384.jpg)
It works by collecting aerosols and identifies the presence of dangerous pathogens using sensitive, specific and rapid detection in near-real time without laboratory analysis
This is a virtual event and the theme is `Transforming Healthcare beyond Covid’
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
It has planned an investment of over Rs 80 crore in the next five years
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
The company plans to raise US $ 15 million
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
Subscribe To Our Newsletter & Stay Updated
